(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Game theory explains why reasonable parents make vaccine choices that fuel outbreaks - 2Whale stranded in the Baltic Sea swims free again. It still faces a tough task
- 3The Most Well known Online Entertainment Forces to be reckoned with of 2023
- 4Visual communication Programming for Fledglings
- 520-year-old who threatened German train attack remanded in custody
- Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test
- Old photos misrepresented as aftermath of political party supporters' brawl in Bangladesh
- Over 250,000 cases of shredded cheese recalled over possible metal fragments
- What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- Italy Brings In New Measures In 2026 To Tackle Overtourism
- Zelensky names spy chief to head presidential office after corruption row
- Tens of thousands protest as far-right AfD forms new youth group
- How Would You Like to Deal with Your Funds?
- Hamas urges Hezbollah to kidnap Israeli soldiers in wake of Knesset passing death penalty bill
